IAP15 Rec'd PCT/PTO 10 NOV 2006

PTO-1390 (Rev. 07-2005)

Approved for use through 03/31/2007. OMB 0651-0021

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE (10,590,687) INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE (24 February 2005) TITLE OF TINZ.2005/1000135 SIRKE DIVING TITLE THE TRANSENDOTHELIAL MIGRATION OF CELLS SUCH AS LEUKOCYTES OR TUNDING CELLS BY A CO-BINDING SUBSTANCE AND USES THEREOF APPLICANT(S) FOR DOVEO/US SIRKE DIVINGSTRA et al. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (3), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. Is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Application as filed (35 U.S.C. 371(c)(2)). a. Is attached hereto (required only if not communicated by the International Bureau). b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. are attached hereto (required only if not communicated by the International Bureau). b. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). A neglish language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). A neglish language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). A neglish language transla	TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)	ATTORNEY'S DOCKET NUMBER 313632002400					
PCTNL2005/000135 24 February 2005 24 February 2004 TITLE OF INVENTION METHOD FOR INHIBITING THE TRANSENDOTHELIAL MIGRATION OF CELLS SUCH AS LEUKOCYTES OR TUMOR CELLS BY A CD-BINDING SUBSTANCE AND USES THEREOF APPLICANT(S) FOR DO/EO/US Sipke DIJASTRA et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (e)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Application as filed (35 U.S.C. 371(e)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application as filed (35 U.S.C. 371(e)(2)). a. are attached hereto (required only if not communicated by the International Bureau). b. have been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(e)(3)). a. are attached hereto (required only if not communicated by the International Bureau). b. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made;		10/590,687					
METHOD FOR INHIBITING THE TRANSENDOTHELIAL MIGRATION OF CELLS SUCH AS LEUKOCYTES OR TUMOR CELLS BY A CD-BINDING SUBSTANCE AND USES THEREOF APPLICANTS (5) FOR DOFCOUS SIDE DIKSTRA et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. in as been communicated by the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto (required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made; however, the time limit for making such amendments							
APPLICANT(S) FOR DO/EC/US Sipke DIJKSTRA et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EC/US) the following items and other information: 1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made, however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the amenexes of the International Preliminary Examination Report under PCT Article 3 (35 U.S.C. 371(c)(5)). 11. X. An Information Disclosure Statement under 37 CFR 1.97 and 1.98, (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A perliminary amendment. 14. An Application Data Sh	TITLE OF INVENTION METHOD FOR INHIBITING THE TRANSENDOTHELIAL MIGRATION OF CELLS SUCH AS LEUKOCYTES OR						
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made, however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the amenexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(6)). 11. X. An Information Disclosure Statement under 37 CFR 1.97 and 1.98, (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A peliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specific	APPLICANT(S) FOR DO/EO/US						
1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. Is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 4. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13(er.2 and 37 CFR 1.821 – 1.825.		/US) the following items and other information:					
This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. Is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. Is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. Is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the amenxes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information Included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825.		,					
include items (5), (6), (9) and (21) indicated below. 4. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. is has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. is attached hereto. c. is a et attached hereto (required only if not communicated by the International Bureau). b. is attached hereto (required only if not communicated by the International Bureau). c. is attached hereto (required only if not communicated by the International Bureau). c. is attached hereto (required only if not communicated by the International Bureau). d. is attached hereto (required only if not communicated by the International Bureau). c. is have not been made; however, the time limit for making such amendments has NOT expired. d. is have not been made and will not be made. 8. is An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. is An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. is An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. is An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. is An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. is A preliminary amendment. 14. is An Application Data Sheet under 37 CFR 1.76. 15. is A substitute specification. 16. is A power of attorney and/or chan	2. This is a SECOND or SUBSEQUENT submission of items concerning a s	ubmission under 35 U.S.C. 371.					
5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) a.		U.S.C. 371(f)). The submission must					
a. is attached hereto (required only if not communicated by the International Bureau). b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	4. The US has been elected (Article 31).						
b. has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2))						
c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a is attached hereto. b has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a are attached hereto (required only if not communicated by the International Bureau). b have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13/er.2 and 37 CFR 1.821 – 1.825.	a. is attached hereto (required only if not communicated by the International Bureau).						
An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	b. has been communicated by the International Bureau.						
a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	c. is not required, as the application was filed in the United States Receiving Office (RO/US).						
b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	a. is attached hereto.						
a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	b. has been previously submitted under 35 U.S.C. 154(d)(4).						
b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	7. Amendments to the claims of the International Application under PCT Arti	cle 19 (35 U.S.C. 371(c)(3))					
c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	a. are attached hereto (required only if not communicated by the Internal	tional Bureau).					
d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	b. have been communicated by the International Bureau.						
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	c. have not been made; however, the time limit for making such amendments has NOT expired.						
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	d. have not been made and will not be made.						
An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. x An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. x An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
11. x An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3 pages) 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	Items 11 to 20 below concern document(s) or information included:						
13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	11. x An Information Disclosure Statement under 37 CFR 1.97 and 1.98. (3	pages)					
An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	12. An assignment document for recording. A separate cover sheet in compli	ance with 37 CFR 3.28 and 3.31 is included.					
A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	13. A preliminary amendment.						
A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	4. An Application Data Sheet under 37 CFR 1.76.						
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	15. A substitute specification.						
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).	16. A power of attorney and/or change of address letter.						
	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825.						
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).	8. A second copy of the published International Application under 35 U.S.C. 154(d)(4).						
	19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. PCT/NL2005/000135		ATTORNEY'S DOCKET NUMBER 313632002400						
20. x Other items or information: PTO/SB/08a/b Form (1 page plus duplicate) References (8) Return Receipt Postcard								
The follo	owing fees hav	e been submitt	ed			CALCULATION	S PTO USEONLY	
	-		a))		\$300	\$	3 110 OGLONE!	
22. Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)				\$				
23. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB \$400 All other situations \$500				\$				
	TOTAL OF 21, 2	2 and 23 =				\$ 0.0	00	
sequen electror	Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.			orogram listing in an				
Total Sheets	Extra Sheets		additional 50 or fraction up to a whole number)		RATE			
- 100 =	/50 =				x \$250.00	\$		
			e, examination fee, or the e (37 CFR 1.492(h)).	oath	or declaration	\$		
CLAIMS	NU	MBER FILED	NUMBER EXTRA		RATE			
Total clain		- 20 =		×				
Independent of		- 3 =		×				
MULTIPLE DEPI	ENDENT CLAIM(s) (if applicable)		+				
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.				\$ 0.0	00			
					SUBTOTAL =	\$ 0.0	10	
			ranslation later than 30 m	nonth		\$		
claimed priority date (37 CFR 1.492(i)).			'AL NATIONAL FEE =	\$ 0.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$					
-2			\$					
TOTAL FEES ENCLOSED =			\$ 0.00					
	-					Amount to be refunded:	\$	
						Amount to be charged	\$	

PTO-1390 (Rev. 07-2005)

Approved for use through 03/31/2007. OMB 0651-0021

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Onder the Paperwork Reduction Act of 1995, no persons are t	equired to respond to a conection or inform	audit uness it un	splays a valid Civib Control Humber.				
a. A check in the amount of \$	to cover the above fees is enc	losed.					
b. Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed.	in the amount of \$	0.00	to cover the above fees.				
c. x The Commissioner is hereby authorized to ch		required, or cred	dit any overpayment to Deposit				
Account No A duplicate-copy of this sheet is enclosed. d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card Information							
should not be included on this form. Provide credit card information and authorization on PTO-2038 NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be							
filed an granted to restore the International Applic	ation to pending status.						
	10.0	-f1 \					
SEND ALL CORRESPONDENCE TO:	SIGNA	TURE	undy-				
Kate H. Murashige MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100		12-1-11 84					
San Diego, California 92130-2040 (858) 720-5112	NAME	Kate H. M	urasnige				
CUSTOMER NUMBER: 25225		29,9	959				
	REGIS	TRATION NUM	BER				
U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/590,687	INTERNATIONAL APPLICATION NO. PCT/NL2005/000135		TORNEY'S DOCKET NUMBER 313632002400				
I hereby certify that this correspondence is being de No. EV 915687355 US, in an envelope addressed to 1450, on the date shown below. Dated: November 6, 2006 Signatur	b: MS PCT, Commissioner for Patent	s, P.O. Box 145	i0, Alexandria, VA 22313-				